1 BTC
=
- USD
Prestige Consumer Healthcare Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Market Statistics
Trading Metrics
How to Buy PBH
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy PBH
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe National Advertising Division reviewed advertising claims for eosera Inc.'s Ear Wax MD product in a challenge brought by Prestige Consumer Healthcare Inc. (marketer of Debrox). NAD found some establishment and mechanism-of-action claims were supported, but recommended discontinuing or modifying comparative superiority claims and unqualified effectiveness claims that overstated results. eosera agreed to comply with NAD's recommendations.
Prestige Consumer Healthcare announced a definitive agreement to acquire the Breathe Right brand for $1.045 billion. The acquisition will expand Prestige's consumer health portfolio in sleep and breathing categories and includes other brands like Dimetapp. The deal is expected to close in H1 fiscal 2027 and should boost margins and free cash flow. However, the stock shows technical weakness, trading below its moving averages with negative MACD signals.
Prestige Consumer Healthcare has agreed to acquire Breathe Right® and other brands from Foundation Consumer Healthcare for $1.045 billion ($900 million net of tax benefits). The acquisition includes the iconic #1 nasal strip brand and other established brands like Dimetapp® and Anbesol®. The deal is expected to close in fiscal 2027 and is projected to be immediately accretive to margins and EPS, with strong free cash flow generation supporting rapid deleveraging.
The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.
Prestige Consumer Healthcare will release its fiscal 2026 second quarter and first half earnings on November 6, 2025, before market opening, with a conference call at 8:30 a.m. ET to discuss results.